the more severe histologic subtypes of focal proliferative and sclerosing disease has reduced O-linked sialic acid and galactosylation than samples from normal controls, and that all groups of IgAN patients have increased exposure of N-acetylgalactosamine residues in their IgA1 compared with normal controls. This work is consistent with previous work that also found decreased sialation in IgAN patients (see e.g., [2] and others therein). The decreased sialation may be fundamental in the pathogenesis of IgAN as desialation may further expose IgA1 to degalactosylation. Such aberrantly glycosalted IgA1 may be important in the pathogenesis of IgAN because it may be deposited in the mesangium. Whether fundamental to the pathogenesis or not, we just want to note that desialation may be a useful point at which to intervene for therapy for IgAN. It may be possible to screen for and design medicinals that specifically block the desialation of IgA1 without unacceptable side effects. We further note that there is at least a small possibility that a useful sialation inhibitor not only already exists, but is also approved for use worldwide. Indeed, neuraminic acid is a synonym for sialic acid. Two neuraminidase inhibitors-oseltamivir and zanamivir-are currently licensed and in use worldwide for treatment and immediate prophylaxis for influenza virus infection [3] . While designed to work against the viral neuraminidase, there is at least some evidence that these medicines are also active against a mammalian neuraminidase [4] . Neuraminidase inhibitors-oseltamivir and zanamivir or others-would be a much needed addition to the treatment armamentarium for IgAN and are worthy of further consideration and potential study.
Thrombocytopenia induced by nicotinamide in hemodialysis patients
To the Editor: Recently, Takahashi [1] proposed in an article in Kidney International the prescription of nicotinamide in order to control phosphorus level in hemodialysis patients. Nicotinamide is a circulating form of nicotinic acid. It was suggested that nicotinamide is probably an effective inhibitor of phosphorus absorption in the intestine. Serum phosphorus level decreased in the study in 65 hemodialysis patients from 2.23 ± 0.48 mmol/L to 1.74 ± 0.42 mmol/L after 12 weeks of treatment. The authors concluded that nicotinamide may provide an alternative for controlling hyperphosphatemia in hemodialysis patients.
In our dialysis unit, where we treat 100 patients, the control of phosphoremia is essentially obtained by diet and prescription of sevelamer [2] . Mean phosphorus level during the last 6 months was 1.77 ± 0.36 mmol/L. Nevertheless, some patients did not reach this level. We prescribed nicotinamide in 6 of them at a dosage of 1000 mg/day. Because a transitory decline in platelet count was described in 1 out 65 patients in the Japanese study, we controlled the platelet count every 2 weeks. In 1 patient the platelet count remained stable, but in 5 of them we observed a dramatic decrease in the platelet count within 3 months of prescription.
Data are expressed as mean ± standart deviation in lL, and a P value of less than 0.05 was considered statistically significant. The mean platelet count 3 months before the prescription of nicotinamide was 188,000 ± 17,000. The mean platelet count during the 3 months of prescription was 122,000 ± 41,000 (P < 0.001). Ten days after discontinuation of the drug the mean platelet count increased to 150,000 ± 9100 (P < 0.01). For each patient, the thrombocytopenia was significant (P < 0.001). We looked at the overall prescriptions of our 6 patients: the only one in common was the prescription of sevelamer, which is not described as inducing a thrombocytopenia. Nicotinamide has been given over the past 40 years at high doses for a variety of therapeutic applications [3] . Nicotinic acid and its derivatives were seldom reported to induce thrombocytopenia [4, 5] . The mechanism of this side effect has not been completely elucidated to date: thrombocytopenia may result from decreased levels of thyroxin-binding globulin induced by nicotinic acid or one of its derivatives. We suggest to control very carefully the prescription of nicotinamide in patients undergoing hemodialysis, and probably to insist more on diet prescription than on drugs to control hyperphosphatemia.
Muscle IGF-I levels in hemodialysis patients
To the Editor: We read with great interest Wang et al's paper [1] describing reduced skeletal muscle mRNA levels for insulin-like growth factor (IGF)-IEa, IGF-II, and the IGF type 1 receptor in hemodialysis (HD) patients. While the low levels of IGF-IEa mRNA relative to healthy controls is anticipated, the elevated muscle IGF-I protein level (mIGF-I) reported is at odds with the diminished levels, relative to healthy controls previously reported in our HD patients [2] and animal models of chronic renal failure (CRF) (e.g. [3] ). An obvious difference between these studies is that in contrast to our patients and CRF rats, the HD patients recruited by Wang et al were not muscle wasted. This supports our contention that mIGF-I may play an important role in muscle atrophy in CRF populations.
Notwithstanding species and methodologic differences, we were also surprised by the huge disparity in mean mIGF-I levels reported by this group for HD patients and CRF rats [1, 3] . Assuming a protein content of 15.5% in wet skeletal muscle for nonobese humans [4] , the 131 and 100 ng IGF-I/mg wet muscle values reported by Wang et al convert to 845 and 645 ng IGF-I/mg muscle protein for HD patients and controls, respectively. These values are 1 to 2×10 5 greater than those reported by Ding et al (0.0042 and 0.0069 ng/mg muscle protein for CRF and control rats, respectively). Are the units correctly stated in these papers? Additionally, the serum IGF values in Wang et al's paper need to be reported as ng/mL, not lg/mL, to be correct.
